2 results
Approved WMOWill not start
The primary objective of this study is to determine the maximum tolerated dose (MTD) for the administration of S80880.Secondary objectivesTo evaluate the safety profile of S80880.To describe the pharmacokinetics (PK) profile of S80880 administered…
Not approvedWill not start
The primary objective of this study is to demonstrate that the IOP-lowering efficacy of Travoprost Ophthalmic Solution, 0.004% (preserved with POLYQUAD) is noninferior to Timolol Ophthalmic Solution (0.5% or 0.25%) in pediatric glaucoma patients.